LB Pharmaceuticals Inc
LBRX
$23.91
$0.331.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | 74.92% | 81.63% | 68.50% | ||
| Total Depreciation and Amortization | 1,520.00% | 2,483.33% | 2,483.33% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 118.41% | -92.54% | -30.84% | ||
| Change in Net Operating Assets | 99.03% | -120.51% | -131.68% | ||
| Cash from Operations | 84.69% | 56.48% | 28.28% | ||
| Capital Expenditure | 100.00% | 85.37% | 87.23% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -252.94% | -63.90% | 109.61% | ||
| Cash from Investing | -255.28% | -63.77% | 109.57% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 1,639,885.00% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | 1,518,560.00% | -- | -- | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 3,626.45% | 50.82% | -264.65% | ||